Tocagen Names Jamey Skillings, M.D., Chief Medical Officer
Pharmaceutical Executive Brings Additional Expertise in Oncology Drug Development and Commercialization
Oversaw Approvals of Numerous Oncology Products, including Avastin®, Xalkori® and Erbitux®
SAN DIEGO, March 25, 2014 -- (Healthcare Sa... Biopharmaceuticals, Oncology, PersonnelTocagen, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 25, 2014 Category: Pharmaceuticals Source Type: news
Trials in Esophageal Ca, HCC Fall Short
SAN FRANCISCO (MedPage Today) -- Patients with esophageal cancer derived no survival benefit with the addition of cetuximab to chemoradiation, while everolimus fared no better in a trial of patients with hepatocellular carcinoma (HCC) that had progressed during or after treatment with sorafenib. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 19, 2014 Category: Gastroenterology Source Type: news
European Commission approves update of Erbitux metastatic colorectal cancer labeling to patients with RAS wild-type tumors
Merck Serono, the biopharmaceutical division of Merck, has announced that the European Commission has approved the Type II variation to amend the Erbitux® (cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC). The approval of the European Commission follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) (issued in November 2013) and is based on the totality of data emerging on the role of mCRC RAS tumor status in the benefit - risk profile of the drug. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 24, 2013 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news
EGF receptor ecto-domain mutations: When to screen and when not to screen
The epidermal growth factor receptor (EGFR) is expressed in normal colonic cells and is activated by specific peptide growth factors that regulate cell proliferation, survival and differentiation. Increased expression and activation of the EGFR has been observed in the majority of colorectal carcinoma (CRC), suggesting that the EGFR pathway plays an important role in colon carcinogenesis.The monoclonal antibodies cetuximab and panitumumab are capable of blocking EGFR activity and have shown clinical activity in patients with metastatic CRC (mCRC). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 24, 2013 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news
European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors
The European Commission's approval is based on the CHMP positive opinion
Label update comes in response to new biomarker data obtained from the OPUS study
DARMSTADT, Germany, Dec. 23, 2013 -- (Healthcare Sales & Marketing Network) -- Merck Serono, t... Biopharmaceuticals, Oncology, RegulatoryMerck Serono, Erbitux, cetuximab, metastatic colorectal cancer, RAS tumor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 23, 2013 Category: Pharmaceuticals Source Type: news
Cetuximab fails in second-line combination for recurrent NSCLC
Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 13, 2013 Category: Cancer & Oncology Source Type: news
Cetuximab fails in second-line combination for recurrent NSCLC
Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - December 13, 2013 Category: Cancer & Oncology Source Type: news
No Way to Identify Which NSCLC Would Benefit From CetuximabNo Way to Identify Which NSCLC Would Benefit From Cetuximab
No PFS benefit seen for second-line cetuximab in advanced non-small-cell lung cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Four-drug regimen shows first-line efficacy in advanced NSCLC
A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer, US researchers report. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 2, 2013 Category: Cancer & Oncology Source Type: news
Four-drug regimen shows first-line efficacy in advanced NSCLC
A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer, US researchers report. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - December 2, 2013 Category: Cancer & Oncology Source Type: news
New biomarker data from OPUS receives CHMP positive opinion
Merck Serono, the biopharmaceutical division of Merck, has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on a variation to the Erbitux® (cetuximab) product information, updating the assessment of benefit-risk in patients with metastatic colorectal cancer (mCRC). (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 22, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: Industry News Oncology Latest News Source Type: news
FIRE-3: Kindling for a CRC Practice Change?FIRE-3: Kindling for a CRC Practice Change?
Dr. David Kerr reports on provocative data from the FIRE-3 study indicating that cetuximab plus FOLFIRI confers a 7.5-month survival advantage in patients with wild-type KRAS colorectal cancer. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 14, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Cetuximab No Benefit With Chemoradiation in Lung Cancer Cetuximab No Benefit With Chemoradiation in Lung Cancer
Adding the targeted agent to chemoradiation did not improve clinical efficacy, but increased toxicity in patients with stage III non-small cell lung cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 29, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Cetuximab and Chemoradiation in Nasopharyngeal CarcinomaCetuximab and Chemoradiation in Nasopharyngeal Carcinoma
Learn about treatment compliance, acute toxicities and the short-term curative effects of combining cetuximab with chemoradiation following induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma. Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 28, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Germany's Merck sees long-term growth in cancer drug Erbitux
DARMSTADT, Germany (Reuters) - German healthcare company Merck KGaA expects to get a long-term boost from study results in June that showed its main cancer drug Erbitux has an edge over rival product Avastin. (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
